Overexpression of EGFR or the ability of mutant versions to control downstream signaling is observed in pancreatic cancer. (Fitzgerald et al., 2015; Oliveira-Cunha et al., 2011). This evidence concerns the gene EGFR and familial pancreatic carcinoma.